Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.
Al-Khawaldeh I, Al Yasiri MJ, Aldred GG, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Martin MP, Miller DC, Shrives HJ, de Souza JV, Stewart HL, Temple M, Thomas HD, Totobenazara J, Tucker JA, Tudhope SJ, Wang LZ, Bronowska AK, Cano C, Endicott JA, Golding BT, Hardcastle IR, Hickson I, Wedge SR, Willmore E, Noble MEM, Waring MJ. Al-Khawaldeh I, et al. Among authors: willmore e. J Med Chem. 2021 Jul 22;64(14):10001-10018. doi: 10.1021/acs.jmedchem.0c01249. Epub 2021 Jul 2. J Med Chem. 2021. PMID: 34212719
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Lourenco LM, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR. Willoughby CE, et al. Among authors: willmore e. J Clin Invest. 2020 Jan 2;130(1):258-271. doi: 10.1172/JCI127483. J Clin Invest. 2020. PMID: 31581151 Free PMC article.
Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
Barrow TM, Nakjang S, Lafta F, Bilotkach K, Woodhouse L, Junge G, Tudhope SJ, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Strathdee G. Barrow TM, et al. Among authors: willmore e. Br J Cancer. 2021 Jan;124(2):474-483. doi: 10.1038/s41416-020-01117-8. Epub 2020 Oct 21. Br J Cancer. 2021. PMID: 33082556 Free PMC article.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. Herriott A, et al. Among authors: willmore e. Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287. Oncotarget. 2015. PMID: 26539646 Free PMC article.
Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL, Crawford C, Mulligan E, Summerfield G, Newton P, Wallis J, Mainou-Fowler T, Evans P, Bedwell C, Durkacz BW, Willmore E. Elliott SL, et al. Among authors: willmore e. Br J Haematol. 2011 Jan;152(1):61-71. doi: 10.1111/j.1365-2141.2010.08425.x. Epub 2010 Nov 18. Br J Haematol. 2011. PMID: 21083655 Free article.
58 results